who created retatrutide UK: New Triple-Agonist Weight Loss Injection Explained Why Retatrutide Is Gaining Attention

Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM, Ayala JE

Retatrutide clinical trial results The phase 2 trial, published in the New England Journal of Medicine, tested retatrutide at doses ranging from 1 mg to 12 mg weekly in adults with obesity

Considering Alternative Medications Tirzepatide (brand names Mounjaro and Zepbound) represents another GLP-1 medication option, though it comes with similar cost challenges

While this small increase is not typically clinically significant, patients with underlying cardiac arrhythmias or those sensitive to heart rate changes should be monitored

Retatrutide remains investigational and is not commercially available, with access limited to clinical trial participation